Trevena, Inc. (TRVN)

Market Cap	24.01M
Revenue (ttm)	-419,000
Net Income (ttm)	-60.62M
Shares Out	6.83M
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Nov 10, 2022

Volume	17,240
Open	3.44
Previous Close	3.46
Day's Range	3.39 - 3.5
52-Week Range	2.38 - 19
Beta	1.86
Analysts	Buy
Price Target	1.87 (-45.8%)
Earnings Date	Nov 9, 2022

About TRVN

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agon...

• Industry: Biotechnology
• IPO Date: Jan 31, 2014
• CEO: Carrie Bourdow
• Employees: 43
• Stock Exchange: NASDAQ
• Ticker Symbol: TRVN

Full Company Profile

Financial Performance

In 2021, Trevena's revenue was $567,000, a decrease of -81.52% compared to the previous year's $3.07 million. Losses were -$51.59 million, 75.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for TRVN stock is "Buy." The 12-month stock price forecast is 1.87, which is a decrease of -45.80% from the latest price.

Price Target

$1.87

(-45.80% downside)

Analyst Consensus: Buy

Stock Forecasts